Recombinant hcmv and rhcmv vectors and uses thereof
AssigneeOregon Health & Science University
InventorsLouis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, scott G. Hansen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Claims18
1-20. (canceled)
A recombinant viral vector comprising a nucleic acid sequence encoding a human cytomegalovirus (HCMV) or rhesus cytomegalovirus (RhCMV) backbone vector and at least one heterologous antigen, wherein the at least one heterologous antigen is a pathogen-specific antigen or a tumor antigen, and wherein the recombinant viral vector:
- (a) comprises a deletion in the HCMV UL115 gene or RhCMV homolog thereof that eliminates expression of a functional gL protein, (b) is deficient in host to host spread, (c) infects a HCMV or RhCMV seropositive subject upon administration of said recombinant viral vector, and (d) induces and maintains a long-term effector memory T cell response to the at least one heterologous antigen in the seropositive subject.
Dependencies are inferred from the claim text.